Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 Phase 1 Study in Healthy Chinese Participants
NCT07787611Phase 1Completed
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWN109 (2 cohorts), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Incidence of adverse events. Started Jun 2025; status: completed.
02
Drugs
MWN109
Beyond the preview
Go deeper on NCT07787611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787611.